United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 1

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 1 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderInspireMD · 56

Strongest available pathDelcath · +57.1%

Widest latest marginDexcom · 17.9%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1NSPR · Nasdaq

InspireMD

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2005Boston, Massachusetts$42.6M market cap

View full Companies Radar profile

56Moderate

Snapshot price$0.91as of page date

Monthly-close return-77.8%five-year window

FY2025 revenue$0.01BInspireMD, Inc.

Net margin-543.3%FY2025

P/E snapshot-1.9xone ratio, not a verdict

Prism attention4.6%share across these five

Filing track recordRevenue, USD billions

+99.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 18.9%

52-week position14% through range

$0.63$2.57

News mentions631

Community mentions0partial coverage

U.S.-scope patents1

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal83/100
Management stability90/100
Market position7/100
Capital-event signal75/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2DXCM · Nasdaq

Dexcom

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1999WILMINGTON$34.02B market cap

View full Companies Radar profile

55Moderate

Snapshot price$90.14as of page date

Monthly-close return-34.1%five-year window

FY2025 revenue$4.66BDEXCOM INC

Net margin17.9%FY2025

P/E snapshot35.6xone ratio, not a verdict

Prism attention61.8%share across these five

Filing track recordRevenue, USD billions

+90.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 17.5%

52-week position94% through range

$54.11$92.59

News mentions8.5K

Community mentions83.7Kpartial coverage

U.S.-scope patents4656

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal82/100
Management stability90/100
Market position7/100
Capital-event signal64/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 11 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3DCTH · Nasdaq

Delcath

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1987New York City, New York$569.1M market cap

View full Companies Radar profile

54Moderate

Snapshot price$16.40as of page date

Monthly-close return+57.1%five-year window

FY2025 revenue$0.09BDELCATH SYSTEMS, INC.

Net margin3.2%FY2025

P/E snapshot1640.0xone ratio, not a verdict

Prism attention5.8%share across these five

Filing track recordRevenue, USD billions

+2297.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021 · CAGR 121.3%

52-week position89% through range

$8.12$17.42

News mentions794

Community mentions116partial coverage

U.S.-scope patents86

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal78/100
Management stability90/100
Market position3/100
Capital-event signal80/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4PODD · Nasdaq

Insulet

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2000Boston, Massachusetts$10.29B market cap

View full Companies Radar profile

53Moderate

Snapshot price$148.4as of page date

Monthly-close return-47.8%five-year window

FY2025 revenue$2.71BINSULET CORP

Net margin9.1%FY2025

P/E snapshot27.8xone ratio, not a verdict

Prism attention20.6%share across these five

Filing track recordRevenue, USD billions

+146.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2023, FY2024, FY2025 · CAGR 25.3%

52-week position10% through range

$126.4$354.9

News mentions2.8K

Community mentions1.3Kpartial coverage

U.S.-scope patents1347

Prism InsightsWhat sits behind the readiness signal
Observed risk 10/100higher means more observed risk

Earnings signal68/100
Management stability90/100
Market position14/100
Capital-event signal79/100
Innovation pulse18/100

Management signal

No leadership-churn flag in the model; 16 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 3 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 2 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 4 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5TNDM · Nasdaq

Tandem Diabetes

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2008San Diego, California$1.48B market cap

View full Companies Radar profile

52Moderate

Snapshot price$21.28as of page date

Monthly-close return-82.2%five-year window

FY2025 revenue$1.01BTANDEM DIABETES CARE INC

Net margin-20.2%FY2025

P/E snapshot124.7xone ratio, not a verdict

Prism attention7.2%share across these five

Filing track recordRevenue, USD billions

+44.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 9.6%

52-week position54% through range

$11.46$29.65

News mentions991

Community mentions156partial coverage

U.S.-scope patents699

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal61/100
Management stability90/100
Market position7/100
Capital-event signal74/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Delcath

+57.1%

Dexcom

-34.1%

Insulet

-47.8%

InspireMD

-77.8%

Tandem Diabetes

-82.2%

Latest revenue

USD billions, official filing scope shown on each company card.

Dexcom

$4.66B

Insulet

$2.71B

Tandem Diabetes

$1.01B

Delcath

$0.09B

InspireMD

$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Dexcom

17.9%

Insulet

9.1%

Delcath

3.2%

Tandem Diabetes

-20.2%

InspireMD

-543.3%

Prism news attention

Normalized share across these five names; attention is not quality.

Dexcom

61.8%

Insulet

20.6%

Tandem Diabetes

7.2%

Delcath

5.8%

InspireMD

4.6%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Dexcom leads the conversation

It holds 61.8% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $4.66B.

Price path

Delcath leads the available price paths

Its monthly-close return is +57.1% for the five-year window. At the other end, Tandem Diabetes is -82.2% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Dexcom has the widest latest margin

Its FY2025 net margin is 17.9%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

InspireMD shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -1.9x while its five-year window price return is -77.8%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DXCM

Dexcom

8,512available Prism news records

Prism top themes

Price action & investor response

415

Macro demand & rates

256

Earnings & financial performance

206

Legal, arbitration & regulatory

148

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-18.8%1,611 latest 12m vs 1,983 prior 12m

Machine-classified coverage tone

80.6% positive+18.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

continuous glucose monitor 247remote glucose monitoring 232flash glucose monitoring 198smartwatch health monitor 188interstitial glucose monitoring 166advanced diabetes devices 145self-monitoring blood glucose 140glucose trends analysis 131

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-28 · trend and themes shown through 2026-06

Areas of research · PODD

Insulet

2,836available Prism news records

Prism top themes

Price action & investor response

235

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Macro demand & rates

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+31.7%581 latest 12m vs 441 prior 12m

Machine-classified coverage tone

75.9% positive-14.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

advanced diabetes devices 84stock performance 76insulin pump alarms 70automated insulin delivery 66insulin pump delivery 56stock price 53share price 48insulin administration 48

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-18 · trend and themes shown through 2026-06

Areas of research · TNDM

Tandem Diabetes

991available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+9.0%157 latest 12m vs 144 prior 12m

Machine-classified coverage tone

83.3% positive-3.2 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

advanced diabetes devices 69insulin pump alarms 48insulin pump delivery 39automated insulin delivery 38insulin administration 30insulin-dependent diabetes control 29insulin vial storage 25type 1 diabetes insulin regimen 24

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-05–2026-06-12 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

DXCM

Dexcom

83,701 mentions

Products, pricing and logistics

72,915

Stock and valuation

596

Workplace and hiring

139

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 83,701 records remained after filtering.

DCTH

Delcath

116 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 116 records remained after filtering.

PODD

Insulet

1,334 mentions

Products, pricing and logistics

868

Stock and valuation

Workplace and hiring

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 1,334 records remained after filtering.

TNDM

Tandem Diabetes

156 mentions

Products, pricing and logistics

Stock and valuation

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 156 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

NSPR

InspireMD

through 2026-04-03

Earnings releases 18Leadership changes 5Business contracts 1Company announcements 1

2026-04-03
Business contracts
We have entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with BTIG, LLC, or BTIG, as our sales agent, dated April 3, 2026, relating to the sale of shares of our common stock, $0.0001 par value per share, offered by this prospectus.
2025-08-05
Earnings releases
For the second quarter of 2025, total revenue increased by $39,000, or 2.3%, to $1,778,000, from $1,739,000 during the second quarter of 2024.
2024-12-12
Leadership changes
Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

DXCM

Dexcom

through 2026-04-30

Earnings releases 61Lawsuits 41Leadership changes 18Company announcements 9Listing / IPO 4

2026-04-30
Earnings releases
Dexcom (Nasdaq:DXCM) today posted first-quarter results that came in ahead of the Wall Street forecast. Shares of DXCM fell nearly 6% to $55.99 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) developer reported profits. of $199.5 million. That equals 51¢ per share on sales of $1.19 billion for the three months ended March 31, 2026.
2026-03-02
Leadership changes
Last week, the company announced that it added Google SVP, Platforms and Devices, Rick Osterloh, to its board as well.
2025-09-11
Lawsuits
A California judge has dismissed several claims against Dexcom (Nasdaq:DXCM) officials related to alleged misrepresentation of sales efforts.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

DCTH

Delcath

through 2026-02-26

Earnings releases 16Regulatory 7Leadership changes 6Board updates 2Asset acquisitions 1

2026-02-26
Earnings releases
Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million , respectively
2025-09-05
Regulatory
The options were granted on August 29, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to the terms and conditions of the Company’s 2023 Inducement Plan; the above-described awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan.
2025-02-14
Board updates
one other independent director to be mutually agreed upon by the companies “in the next few weeks.”

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PODD

Insulet

through 2026-04-09

Earnings releases 47Leadership changes 43Company announcements 10Lawsuits 5M&A 3

2026-04-09
Earnings releases
Based on Insulet’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $783.8 million and a net profit of $101.6 million.
2026-04-06
Leadership changes
Insulet (Nasdaq:PODD) announced on social media today that it appointed a new SVP, chief quality, regulatory and compliance officer.
2026-04-05
Lawsuits
Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation concerning potential violations of the federal securities laws.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TNDM

Tandem Diabetes

through 2026-02-20

Earnings releases 30Lawsuits 14Leadership changes 6Company announcements 1

2026-02-20
Earnings releases
Sales increased 3% year over year to $290.4 million, beating the consensus of $277.03 million.
2025-11-12
Leadership changes
Tandem Diabetes Care, Inc. announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025.
2023-11-06
Lawsuits
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 1–8. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

InspireMD leads the readiness ranking

Its Prism readiness score is 56/100, the highest in this five-company comparison.

Open InspireMD in Companies Radar

Scale and margin leadership sit with Dexcom and Dexcom

Dexcom has the largest displayed latest revenue at $4.66B; Dexcom has the widest displayed latest margin at 17.9%.

Open Dexcom in Companies Radar

Comparisons

Strongest versus weakest available price path

Delcath is +57.1% for its five-year window; Tandem Diabetes is -82.2% for its five-year window.

Open Delcath in Companies Radar Open Tandem Diabetes in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $4.66B for Dexcom to $0.01B for InspireMD. Entity and filing-period labels remain visible on the company cards.

Open Dexcom in Companies Radar Open InspireMD in Companies Radar

Anomalies

InspireMD has the widest attention-readiness rank gap

It ranks #5 by measured news attention (4.6%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open InspireMD in Companies Radar

Insulet shows a price-operating divergence to inspect

Its displayed filing-revenue change is +146.5% while its available monthly-close return is -47.8%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Insulet in Companies Radar

Explanations

Attention measures coverage volume, not quality

Dexcom's 61.8% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Dexcom in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open InspireMD's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 56/100 score.

Open InspireMD in Companies Radar

Stress-test the largest divergence before forming a view

Compare Insulet's profile with Delcath's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Insulet in Companies Radar Open Delcath in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.